var data={"title":"Itraconazole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Itraconazole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6415?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=itraconazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Itraconazole: Patient drug information&quot;</a> and <a href=\"topic.htm?path=itraconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Itraconazole: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708958\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Congestive heart failure:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not administer itraconazole for the treatment of onychomycosis in patients with evidence of ventricular dysfunction, such as congestive heart failure (CHF) or a history of CHF. If signs or symptoms of CHF occur during administration of itraconazole oral solution, reassess continued itraconazole use. If signs or symptoms of CHF occur during administration of itraconazole capsules or tablets, discontinue administration. When itraconazole was administered intravenously (IV) to dogs and healthy human volunteers, negative inotropic effects were seen.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Drug interactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Coadministration of the following drugs is contraindicated with itraconazole: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (eg, dihydroergotamine, ergometrine [ergonovine], ergotamine, methylergometrine [methylergonovine]), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, and ticagrelor. In addition, coadministration with colchicine, fesoterodine, and solifenacin is contraindicated in patients with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in patients who are poor or intermediate metabolizers of CYP2D6 and in patients taking strong or moderate CYP2D6 inhibitors. Coadministration with itraconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185420\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Onmel;</li>\n      <li>Sporanox;</li>\n      <li>Sporanox Pulsepak</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185421\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sporanox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185468\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Azole Derivative;</li>\n      <li>\n        Antifungal Agent, Oral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185425\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Capsule and oral solution formulations are not bioequivalent (oral solution has higher bioavailability) and thus are not interchangeable. Generally, oral solution is the preferred formulation because of improved absorption (IDSA [Kauffman 2007]; HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, invasive (salvage therapy):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer labeling: </i>Oral capsule: 200 to 400 mg daily. For life-threatening infections, administer a loading dose of 200 mg 3 times daily (total: 600 mg daily) for the first 3 days of therapy. Continue treatment for at least 3 months and until clinical and laboratory evidence suggest that infection has resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations:</i> Oral solution: 200 mg twice daily; duration of therapy is a minimum of 6 to 12 weeks, although duration is highly dependent on degree/duration of immunosuppression, disease site, and evidence of disease improvement (IDSA [Patterson 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Blastomycosis:</b> <i>Manufacturer labeling:</i> Oral capsule: Initial: 200 mg once daily; if no clinical improvement or evidence of progressive infection, may increase dose in increments of 100 mg up to maximum of 400 mg daily. Doses &gt;200 mg daily should be administered in 2 divided doses. <b>Note:</b> For life-threatening infections, the US labeling recommends administering a loading dose of 200 mg 3 times daily (total: 600 mg daily) for the first 3 days of therapy. Continue treatment for at least 3 months and until clinical and laboratory evidence suggest that infection has resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative dosing:</i> 200 mg 3 times daily for 3 days, then 200 mg twice daily for 6 to 12 months; in moderately severe to severe infection, therapy should be initiated with ~2 weeks of amphotericin B (Chapman 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Esophageal:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>US labeling:</i> Oral solution: 100 to 200 mg once daily for a minimum of 3 weeks; continue dosing for 2 weeks after resolution of symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing:</i> Oral solution: Fluconazole-refractory disease: 200 mg once daily for 14 to 21 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral solution: 100 to 200 mg once daily for a minimum of 3 weeks; continue dosing for 2 weeks after resolution of symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral capsules: 100 mg once daily for 4 weeks; increase dose to 200 mg once daily in patients with AIDS and neutropenic patients</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing:</i> HIV-infected patients: Oral solution: 200 mg once daily for 14 to 21 days (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oropharyngeal:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>US labeling:</i> Oral solution: 200 mg once daily for 1 to 2 weeks; in patients unresponsive or refractory to fluconazole: 100 mg twice daily (clinical response expected in 2 to 4 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing:</i> Oral solution: Fluconazole-refractory disease: 200 mg once daily for up to 28 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral solution: 200 mg once daily or in divided doses daily for 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral capsules: 100 mg once daily for 2 weeks; increase dose to 200 mg once daily in patients with AIDS and neutropenic patients</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing:</i> HIV-infected patients (alternative agent): Oral solution: 200 mg once daily for 7 to 14 days (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Vulvo-vaginal (uncomplicated) in HIV-infected patients (alternative to preferred therapy) (off-label use):</i> Oral solution: 200 mg once daily for 3 to 7 days (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chromomycosis:</b> Canadian labeling (not in US labeling): Oral: 200 mg once daily for 6 months (when due to <i>Fonsecaea pedrosoi</i>) or 100 mg once daily for 3 months (when due to <i>Cladosporium carrioni</i>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cocc</b>\n      <b>idioidomycosis, extrapulmonary (non-HIV infected) (off-label use): </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Soft tissue infection (not associated with bone infection): 200 mg twice daily for at least 6 to 12 months (IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bone and/or joint infection<b>:</b> 200 mg twice daily for 3 years to lifetime, depending on severity and host immunocompetence.<b> Note:</b> Amphotericin B may be used initially in severe cases and then switched to itraconazole (IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coccidioidal pneumonia (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-HIV infected (<i>symptomatic, chronic cavitary)</i>: </i>Oral: 200 mg twice daily for at least 12 months (IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-infected patients (focal pneumonia):</i> 200 mg twice daily (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coc</b>\n      <b>cidioidal meningitis (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-HIV infected: </i>Oral: 200 mg 2 to 4 times daily; close monitoring required to assure adequate absorption (IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-infected patients</i> (HHS [OI adult 2017]) (alternative agent): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 200 mg 3 times daily for 3 days, then 200 mg twice daily, followed by chronic suppressive therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic suppressive therapy: 200 mg twice daily continued indefinitely, even with increase in CD4 count on ART</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryptococcosis in HIV-infected patients (off-label use) (alternative agent):</b> Oral: <i>Treatment, consolidation therapy: </i>200 mg twice daily for &ge;8 weeks (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Histoplasmosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer labeling:</i> Oral capsule: Initial: 200 mg once daily; if no clinical improvement or evidence of progressive infection, may increase dose in increments of 100 mg up to maximum of 400 mg daily. Doses &gt;200 mg daily should be administered in 2 divided doses. <b>Note:</b> For life-threatening infections, the US labeling recommends administering a loading dose of 200 mg 3 times daily (total: 600 mg daily) for the first 3 days of therapy. Continue treatment for at least 3 months and until clinical and laboratory evidence suggest that infection has resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing:</i> 200 mg 3 times daily for 3 days, then 200 mg twice daily (or once daily in mild-moderate disease) for 6 to 12 weeks in mild-moderate disease or &ge;12 months in progressive disseminated or chronic cavitary pulmonary histoplasmosis; in moderately severe to severe infection, therapy should be initiated with ~2 weeks of a lipid formation of amphotericin B (Wheat 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HIV-</i>\n      <i>infected patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild disseminated disease: Induction and maintenance therapy: 200 mg 3 times daily for 3 days, then 200 mg twice daily for &ge;12 months (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe disseminated disease: Maintenance therapy (following at least 2 weeks of induction therapy with an appropriate agent): 200 mg 3 times daily for 3 days, then 200 mg twice daily for &ge;12 months (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Meningitis: Maintenance therapy (following 4 to 6 weeks of induction therapy with an appropriate agent): 200 mg 2 to 3 times daily for &ge;12 months and until resolution of abnormal CSF findings (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylaxis (off-label use):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Primary prophylaxis in HIV-infected patients:</i> 200 mg once daily; primary prophylaxis is indicated when CD4 count &lt;150 cells/mm<sup>3</sup> and at increased risk of exposure (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Long-term suppression therapy (secondary prophylaxis) in HIV-infected patients:</i> 200 mg once daily; long-term suppressive therapy is indicated in patients who relapse despite appropriate therapy or in patients with CNS or severe disseminated infection (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Microsporidiosis, disseminated (caused by</b> <b><i>Trachipleistophora</i></b> <b>or</b> <b><i>Anncaliia</i></b><b>) in HIV-infected patients (off-label use):</b> Oral: 400 mg once daily in combination with albendazole (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Onychomycosis (fingernail involvement only):</b> Oral capsule: 200 mg twice daily for 1 week; repeat 1-week course after 3-week off-time</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Onychomycosis (toenails due to <i>Trichophyton rubrum</i> or <i>T. mentagrophytes</i>):</b> Oral tablet: 200 mg once daily for 12 consecutive weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Onychomycosis (toenails with or without fingernail involvement): </b> Oral capsule: 200 mg once daily for 12 consecutive weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Canadian labeling (not in US labeling): &quot;Pulse-dosing&quot;: 200 mg twice daily for 1 week; repeat 1-week course twice with 3-week off-time between each course</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paracoccidioidomycosis:</b> Canadian labeling (not in US labeling): Oral capsule: 100 mg once daily for 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Penicilliosis in HIV-infected patients (off-label use) (HHS [OI adult 2017]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary prophylaxis:</i> 200 mg once daily for patients with a CD4 count &lt;100 cells/mm<sup>3</sup> who spend extensive time in northern Thailand, Vietnam, and Southern China, especially rural areas</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> 200 mg twice daily for 8 weeks (mild disease) or 10 weeks (severe infections), then continue with maintenance therapy. In severely ill patients, initiate therapy with 2 weeks of liposomal amphotericin B.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic maintenance (secondary prophylaxis):</i> 200 mg once daily until CD4 count &gt;100 cells/mm<sup>3</sup> for &ge;6 months in response to ART</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pityriasis versicolor:</b> Canadian labeling (not in US labeling): Oral: 200 mg once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sporotrichosis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lymphocutaneous:</i> 200 mg daily for 3 to 6 months (Kauffman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Canadian labeling (not in US labeling): 100 mg once daily for 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Osteoarticular and pulmonary:</i> 200 mg twice daily for &ge;1 years (may use amphotericin B initially for stabilization) (Kauffman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tinea corporis or tinea cruris:</b> Canadian labeling (not in US labeling): Oral capsule: 100 mg once daily for 14 consecutive days or 200 mg once daily for 7 consecutive days. <b>Note:</b> Equivalency between regimens not established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tinea pedis:</b> Canadian labeling (not in US labeling): Oral capsule: 100 mg once daily for 28 consecutive days or 200 mg twice daily for 7 consecutive days. <b>Note:</b> Equivalency between regimens not established. Patients with chronic resistant infection may benefit from lower dose and extended treatment time (100 mg once daily for 28 days).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185447\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=itraconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Itraconazole: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Capsule and oral solution formulations are not bioequivalent (oral solution has higher bioavailability) and thus are not interchangeable. Generally, oral solution is the preferred formulation because of improved absorption (HHS [OI pediatric 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> Limited data available: Infants, Children, and Adolescents: Oral capsule or solution: 2.5 to 5 mg/kg/dose every 12 hours for treatment; for relapse prevention, once daily dose may be considered; usual maximum daily dose: 200 mg/day (Bradley 2015; <i>Red Book </i>[AAP 2015]); some infections may require up to 400 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Indication-specific dosing:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blastomycosis (off-label population) (Chapman 2008; </b>\n      <b>\n        <i>Red Book </i></b>\n      <b>[AAP 2015]):</b> Limited data available: Infants, Children, and Adolescents: Oral capsule or solution:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mild to moderate pulmonary and extrapulmonary disease:</i> 5 mg/kg/dose twice daily for 6 to 12 months; maximum dose: 200 mg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Severe or CNS infection (step down therapy after amphotericin B response):</i> 5 mg/kg/dose twice daily; total therapy duration: At least 12 months; maximum dose: 200 mg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis (HIV-exposed/-positive) (HHS [OI adult 2017]; HHS [OI pediatric 2013]):</b> Oral solution: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Oropharyngeal, treatment (off-label population):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: If fluconazole-refractory: 2.5 mg/kg/dose twice daily for 7 to 14 days; maximum daily dose range: 200 to 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 200 mg once daily for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Esophageal, treatment (off-label population):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 2.5 mg/kg/dose twice daily for at least 21 days and at least 2 weeks following resolution of symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 200 mg once daily for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Vulvovaginal, uncomplicated (off-label use):</i> Adolescents: 200 mg once daily for 3 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Secondary prophylaxis (off-label use):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 2.5 mg/kg/dose twice daily, maximum daily dose: 200 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oropharyngeal candidiasis (suppressive): 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, invasive (off-label use): </b> Oral solution: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary prophylaxis (ESCMID [Hope 2012]): Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>AML and recurrent leukemia:</i> 2.5 mg/kg every 12 hours after last dose of chemotherapy; continue until neutrophil recovery.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HSCT, allogeneic:</i> 2.5 mg/kg every 12 hours after completion of the conditioning regimen; continue until at least day +100.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HSCT, autologous:</i> 2.5 mg/kg every 12 hours after last dose of chemotherapy; continue until neutrophil recovery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis, (HIV-exposed/-positive) (off-label use) (HHS [OI adult 2017]; HHS [OI pediatric 2013]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Mild to moderate infection, non-CNS (eg, focal pneumonitis):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children: Oral solution: 2 to 5 mg/kg/dose 3 times daily for 3 days followed by 2 to 5 mg/kg/dose twice daily; maximum dose: 200 mg/dose. Duration of treatment determined by rate of clinical response. For skeletal infection, 5 mg/kg/dose twice daily for 12 months (Bradley 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: Oral: 200 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Severe infection, non-CNS (with amphotericin B or as step down therapy after amphotericin B response): </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children: Oral: 5 mg/kg/dose twice daily; total therapy duration: at least 12 months; maximum dose: 200 mg/dose. Product formulation not specified.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: Oral: 200 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>CNS disease/meningitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children: Not recommended; drug of choice for this age group is fluconazole.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: Oral: 200 mg 3 times daily for 3 days, then 200 mg twice daily; product formulation not specified.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Relapse prevention:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Oral: 2 to 5 mg/kg/dose twice daily; maximum dose: 200 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oral: 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcus (HIV-exposed/-positive) (off-label use) (HHS [OI pediatric 2013]):</b> Infants and Children: Oral solution: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment, consolidation therapy:</i> Oral solution (preferred): Initial: 2.5 to 5 mg/kg/dose 3 times daily (maximum daily dose: 600 mg daily) for 3 days (9 doses) followed by 5 to 10 mg/kg/day divided once or twice daily (maximum daily dose: 400 mg daily) for a minimum of 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Relapse prevention:</i> 5 mg/kg/dose once daily (maximum daily dose: 200 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis (off-label population) (HHS [OI adult 2017]; HHS [OI pediatric 2013]; IDSA [Wheat 2007]; </b> <b><i>Red Book</i></b><b> [AAP 2015]):</b> Oral solution (preferred): Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Primary prophylaxis in HIV-infected patients:</i> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment, acute primary pulmonary disease:</i> Infants and Children: 2 to 5 mg/kg/dose 3 times daily for 3 days (9 doses) followed by 2 to 5 mg/kg/dose twice daily; maximum dose: 200 mg/dose. Duration of therapy for HIV-exposed/-positive patients is 12 months or for HIV-exposed/-positive children with functional cellular immunity (CD4 percentage &gt;20% or &gt;300 cells/mm<sup>3</sup> if age &ge;6 years) 12 weeks of treatment may be adequate if clinically improved and urine antigen concentrations decreased. For non-HIV-exposed/-positive patients, a duration of 6 to 12 weeks is recommended depending on severity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment, mild disseminated disease: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 2 to 5 mg/kg/dose 3 times daily for 3 days (9 doses) followed by 2 to 5 mg/kg/dose twice daily; maximum dose: 200 mg/dose. Duration for HIV-exposed/-positive patients: At least 12 months. Duration for non-HIV-exposed/-positive: 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 200 mg 3 times daily for 3 days, then 200 mg twice daily. Duration for HIV-exposed/-positive patients: At least 12 months. Duration for non-HIV-exposed/-positive: 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation treatment for moderate-severe to severe disseminated disease, including CNS infection (following appropriate induction therapy): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 2 to 5 mg/kg/dose 3 times daily for 3 days (9 doses) followed by 2 to 5 mg/kg/dose twice daily; maximum dose: 200 mg/dose. Duration for HIV-exposed/-positive patients: 12 months for non-CNS disseminated disease or for &ge;12 months for CNS infection as determined by clinical response. Duration for non-HIV-exposed/-positive: At least 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 200 mg 3 times daily for 3 days (disseminated disease) or until resolution of abnormal CSF findings (CNS infection), then 200 mg twice daily. Duration for HIV-exposed/-positive patients: 12 months for non-CNS disseminated disease or for &ge;12 months for CNS infection as determined by clinical response. Duration for non-HIV-exposed/-positive: At least 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Long-term suppression therapy (secondary prophylaxis):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 5 to 10 mg/kg/dose once daily; maximum dose: 200 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Microsporidiosis, disseminated (caused by</b> <b><i>Trachipleistophora</i></b> <b>or</b> <b><i>Anncaliia</i></b><b>) in HIV-infected patients (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Penicilliosis in HIV-infected patients (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sporotrichosis (off-label population) (Kauffman 2007; </b> <b><i>Red Book</i></b> <b>[AAP 2015]):</b> Limited data available: Infants, Children, and Adolescents: Oral solution (preferred):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Lymphocutaneous or localized cutaneous:</i> 3 to 5 mg/kg/dose twice daily; continue until 2 to 4 weeks after all lesions have resolved, usual total duration: 3 to 6 months; maximum dose: 200 mg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Visceral or disseminated (step down therapy after amphotericin B response):</i> 3 to 5 mg/kg/dose twice daily; continue until total therapy duration: at least 12 months; maximum dose: 200 mg/dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185426\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185427\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The manufacturer's labeling states to use with caution in patients with renal impairment; dosage adjustment may be needed. Limited data suggest that no dosage adjustments are required in renal impairment; wide variations observed in plasma concentrations versus time profiles in patients with uremia, or receiving hemodialysis or continuous ambulatory peritoneal dialysis (Boelaert 1988).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Nondialyzable</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185428\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, use caution and monitor closely for signs/symptoms of toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185395\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sporanox: 100 mg [contains brilliant blue fcf (fd&amp;c blue #1), d&amp;c red #22 (eosine), fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sporanox Pulsepak: 100 mg [contains brilliant blue fcf (fd&amp;c blue #1), d&amp;c red #22 (eosine), fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sporanox: 10 mg/mL (150 mL) [contains propylene glycol, saccharin sodium, sorbitol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Onmel: 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185380\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185398\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Do not administer with antacids. Capsule and oral solution formulations are not bioequivalent and thus are not interchangeable; generally, oral solution is the preferred formulation because of improved absorption (IDSA [Kauffman 2007]; HHS [OI adult 2017; OI pediatric 2013]). Capsule and tablet absorption is best if taken with food; therefore, it is best to administer itraconazole after meals at the same time each day; solution should be taken on an empty stomach. When treating oropharyngeal and esophageal candidiasis, solution should be swished vigorously in mouth (10 mL at a time), then swallowed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185396\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis (capsules):</b> Treatment of pulmonary and extrapulmonary aspergillosis in immunocompromised and nonimmunocompromised patients who are intolerant of or refractory to amphotericin B therapy. <b>Note: </b>IDSA Aspergillosis guidelines recommend amphotericin B formulations for invasive aspergillosis (initial or salvage) only when voriconazole is contraindicated or not tolerated (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Blastomycosis (capsules):</b> Treatment of pulmonary and extrapulmonary blastomycosis in immunocompromised and nonimmunocompromised patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Histoplasmosis (capsules):</b> Treatment of histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis in immunocompromised and nonimmunocompromised patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Onychomycosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules: Treatment of onychomycosis of the toenail, with or without fingernail involvement, and onychomycosis of the fingernail caused by dermatophytes (tinea unguium) in nonimmunocompromised patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets: Treatment of onychomycosis of the toenail caused by <i>Trichophyton rubrum</i> or <i>Trichophyton mentagrophytes</i> in nonimmunocompromised patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oropharyngeal/Esophageal candidiasis (oral solution):</b> Treatment of oropharyngeal and esophageal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Canadian labeling:</i></b> <b>Oral capsules: Additional indications (not in US labeling):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, oral and/or esophageal:</b> Treatment of oral and/or esophageal candidiasis in immunocompromised and immunocompetent patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chromomycosis:</b> Treatment of chromomycosis in immunocompromised and immunocompetent patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatomycoses:</b> Treatment of dermatomycoses due to tinea pedis, tinea cruris, tinea corporis, and of pityriasis versicolor in patients for whom oral therapy is appropriate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Onychomycosis:</b> Treatment of onychomycosis in immunocompromised and immunocompetent patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paracoccidioidomycosis:</b> Treatment of paracoccidioidomycosis in immunocompromised and immunocompetent patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sporotrichosis:</b> Treatment of cutaneous and lymphatic sporotrichosis in immunocompromised and immunocompetent patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45504494\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Candidiasis, vulvo-vaginal in HIV-infected patients (adolescents and adults); Coccidioidal meningitis in HIV-infected patients (adolescents and adults); Coccidioidal pneumonia in HIV-infected patients (adolescents and adults); Coccidioidomycosis (non-HIV infected); Cryptococcosis in HIV-infected patients (adults and adolescents); Histoplasmosis (primary prophylaxis/long-term suppression therapy) in HIV-infected patients (adolescents and adults); Microsporidiosis, disseminated in HIV-infected patients (adolescents and adults); Penicilliosis in HIV-infected patients (adolescents and adults); Additional off-label uses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185476\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Itraconazole may be confused with fluconazole, posaconazole, voriconazole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sporanox may be confused with Suprax, Topamax</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185387\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Diarrhea (3% to 11%), nausea (3% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (4%), chest pain (3%), hypertension (2% to 3%),</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (1% to 10%), dizziness (2% to 4%), anxiety (3%), depression (2% to 3%), fatigue (2% to 3%), pain (2% to 3%), malaise (1% to 3%), abnormal dreams (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3% to 9%), pruritus (&le;5%), diaphoresis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypertriglyceridemia (&le;3%), hypokalemia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (5% to 7%), abdominal pain (2% to 6%), dyspepsia (&le;4%), flatulence (&le;4%), gastrointestinal disease (&le;4%), gingivitis (3%), aphthous stomatitis (&le;3%), constipation (2% to 3%), gastritis (2%), gastroenteritis (2%), increased appetite (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Cystitis (2%), urinary tract infection (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (3%), increased liver enzymes (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes zoster (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Bursitis (3%), myalgia (&le;3%), tremor (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (5% to 9%), upper respiratory tract infection (8%), sinusitis (2% to 7%), cough (4%), dyspnea (2%), pneumonia (2%), pharyngitis (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;2%, postmarketing, and/or case reports: Abnormal urinalysis, acute generalized exanthematous pustulosis, adrenocortical insufficiency, albuminuria, alopecia, anaphylactoid reaction, anaphylaxis, angioedema, anorexia, arthralgia, blurred vision, cardiac arrhythmia, cardiac failure, chills, confusion, decreased libido, dehydration, diplopia, drowsiness, dysgeusia, dysphagia, erectile dysfunction, erythema multiforme, erythematous rash, exfoliative dermatitis, facial edema, gynecomastia, hearing loss, hematuria, hepatic failure, hepatitis, hepatotoxicity, hot flash, hyperbilirubinemia, hyperglycemia, hyperhidrosis, hyperkalemia, hypersensitivity angiitis, hypersensitivity reaction, hypoesthesia, hypomagnesemia, hypotension, impotence, increased blood urea nitrogen, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, insomnia, jaundice, left heart failure, leukopenia, menstrual disease, mucosal inflammation, neutropenia, orthostatic hypotension, pancreatitis, paresthesia, peripheral edema, peripheral neuropathy, pharyngolaryngeal pain, pollakiuria, pulmonary edema, renal insufficiency, rigors, serum sickness, sinus bradycardia, skin photosensitivity, Stevens-Johnson syndrome, tachycardia, thrombocytopenia, tinnitus, toxic epidermal necrolysis, urinary incontinence, urticaria, vasculitis, vertigo, voice disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185401\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to itraconazole or any component of the formulation; concurrent administration with avanafil, cisapride, disopyramide, dofetilide, dronedarone, eplerenone, ergot derivatives, felodipine, irinotecan, isavuconazole, ivabradine, lomitapide, lovastatin, lurasidone, methadone, midazolam (oral), naloxegol, nisoldipine, pimozide, quinidine, ranolazine, simvastatin, ticagrelor, or triazolam; concurrent administration with colchicine, fesoterodine, or solifenacin in patients with varying degrees of renal or hepatic impairment; coadministration with eliglustat in patients who are poor or intermediate metabolizers of CYP2D6 and in patients taking strong or moderate CYP2D6 inhibitors; treatment of onychomycosis (or other non-life-threatening indications) in patients with evidence of ventricular dysfunction, such as congestive heart failure (CHF) or a history of CHF; treatment of onychomycosis in women who are pregnant or contemplating pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concurrent administration with domperidone, eletriptan, fesoterodine in patients with moderate to severe renal or hepatic impairment, or solifenacin in patients with severe renal impairment or moderate to severe hepatic impairment (capsule, oral solution); Concurrent administration with the following drugs (none of which are available in Canada): Astemizole, bepridil, halofantrine, ivabradine, lercanidipine, levacetylmethadol, mizolastine, telithromycin (in patients with severe renal or hepatic impairment), sertindole, terfenadine (capsule, oral solution); treatment of dermatomycosis (tinea pedis, tinea cruris, tinea corporis, pityriasis versicolor) in women who are pregnant or intend to become pregnant (capsule)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185384\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hearing loss: Transient or permanent hearing loss has been reported. Quinidine (a contraindicated drug) was used concurrently in several of these cases. Hearing loss usually resolves after discontinuation, but may persist in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: <b>[US Boxed Warning]: Negative inotropic effects have been observed following intravenous administration. Discontinue or reassess use if signs or symptoms of heart failure (HF) occur during treatment.</b> CHF has been reported, particularly in patients receiving a total daily oral dose of 400 mg. Use with caution in patients with risk factors for HF (COPD, renal failure, edematous disorders, ischemic or valvular disease). Discontinue treatment if signs or symptoms of heart failure develop. In a scientific statement from the American Heart Association, itraconazole has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major); may consider use when treating life-threatening fungal infections (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Rare cases of serious hepatotoxicity (including liver failure and death) have been reported (including some cases occurring within the first week of therapy); hepatotoxicity was reported in some patients without preexisting liver disease or risk factors. Discontinue treatment if signs or symptoms of hepatotoxicity develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Use caution in patients with a history of hypersensitivity to other azoles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: Discontinue if signs or symptoms of neuropathy occur during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cystic fibrosis: Large differences in itraconazole pharmacokinetic parameters have been observed in cystic fibrosis patients receiving the oral solution; if a patient with cystic fibrosis does not respond to therapy, alternate therapies should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor liver function closely. Not recommended for use in patients with active liver disease, elevated liver enzymes, or prior hepatotoxic reactions to other drugs unless the expected benefit exceeds the risk of hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Onychomycosis: <b>[US Boxed Warning]: Use is contraindicated for treatment of onychomycosis in patients with ventricular dysfunction such as heart failure (HF) or a history of HF.</b> Cases of HF, peripheral edema, and pulmonary edema have occurred in this patient population. Due to potential toxicity, the manufacturer recommends confirmation of diagnosis testing of nail specimens prior to treatment of onychomycosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; limited information is available; dosage adjustment may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Additional potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; High potential for interactions: Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients taking CYP 3A inhibitors such as cisapride, pimozide, methadone or quinidine. <b>[US Boxed Warning]: Coadministration with itraconazole can cause elevated plasma concentrations of certain drugs and can lead to QT prolongation and ventricular tachyarrhythmias, including torsades de pointes. Coadministration with methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids, irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, and solifenacin is contraindicated. Coadministration with eliglustat is contraindicated in poor or intermediate metabolizers of CYP2D6 and in patients taking strong or moderate CYP2D6 inhibitors.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral capsules/tablets: Absorption of itraconazole capsules is reduced when gastric acidity is reduced (eg, achlorhydria, acid suppressive therapy) administer capsules or tablets with an acidic beverage (eg, non-diet cola) in patients with reduced gastric acidity and separate administration from acid suppressive therapy (refer to drug interactions section). Monitor for response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solution: Only the oral solution has proven efficacy in oral/esophageal candidiasis; mucosal exposure may vary between the oral solution and capsules. Initiation of treatment with oral solution is not recommended in patients at immediate risk for systemic candidiasis (eg, patients with severe neutropenia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Due to differences in bioavailability, oral capsules and oral solution <b>cannot be used interchangeably.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Itraconazole should NOT be used for voriconazole-refractory aspergillosis because the same antifungal and/or resistance mechanism(s) may be shared by both agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185462\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (strong), P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185389\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8586&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Abemaciclib.  Management: In patients taking abemaciclib at a dose of 200 mg or 150 mg twice daily, reduce the dose to 100 mg twice daily when combined with strong CYP3A4 inhibitors. In patients taking abemaciclib 100 mg twice daily, decrease the dose to 50 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Itraconazole may increase the serum concentration of Aliskiren. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alitretinoin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP3A4 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALPRAZolam: Itraconazole may increase the serum concentration of ALPRAZolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Itraconazole. Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Apixaban.  Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 10 mg twice daily, and avoiding in patients who would otherwise receive 2.5 mg twice daily. Canadian labeling lists any combined use as contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Please refer to the full interaction monograph for details concerning the recommended dose adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Astemizole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Itraconazole may increase the serum concentration of AtorvaSTATin.  Management: Limit atorvastatin to a maximum adult dose of 20 mg/day in patients receiving itraconazole.  Assess clinical response to ensure that the lowest necessary dose of atorvastatin is used. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: Itraconazole may increase the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bictegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Blonanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: Itraconazole may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Itraconazole.  Management: Limit maximum adult itraconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in itraconazole concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose to 50% of usual with a strong CYP3A4 inhibitor; reduce to 25% of usual if used with both a moderate CYP3A4 inhibitor and a CYP2D6 inhibitor, or if a strong CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with strong CYP3A4 inhibitors when possible. If combination cannot be avoided, reduce the brigatinib dose by approximately 50%, rounding to the nearest tablet strength (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromocriptine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Itraconazole may increase the serum concentration of Bromperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of BusPIRone.  Management: Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabazitaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.  Management: Concurrent use of cabazitaxel with strong inhibitors of CYP3A4 should be avoided when possible.  If such a combination must be used, consider a 25% reduction in the cabazitaxel dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.  Management: Avoid use of a strong CYP3A4 inhibitor with cabozantinib if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcifediol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.<b> Exceptions: </b>Clevidipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabidiol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Itraconazole may increase the serum concentration of Cardiac Glycosides.  Management: Consider preemptive cardiac glycoside dose adjustments with initiation / changes / discontinuation of itraconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cariprazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cariprazine.  Management: Cariprazine dose reductions of 50% are required; specific recommended management varies slightly for those stable on cariprazine versus those just starting cariprazine.  See prescribing information or full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib.  Management:  If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest 150 mg).  Resume the prior ceritinib dose after cessation of the strong CYP3A4 inhibitor.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving strong inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clobetasone: Itraconazole may increase the serum concentration of Clobetasone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: Itraconazole may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Itraconazole.  Management: Limit itraconazole to a maximum adult dose of 200 mg/day in patients treated with the elvitegravir/cobicistat/emtricitabine/tenofovir combination product. Dosing recommendations for other cobicistat-containing products are not available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Copanlisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Copanlisib.  Management: If concomitant use of copanlisib and strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg. Monitor patients for increased copanlisib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Orally inhaled fluticasone propionate with a strong CYP3A4 inhibitor is not recommended.<b> Exceptions: </b>Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Systemic). <b> Exceptions: </b>MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic). Fluconazole and isavuconazonium considerations are addressed in separate monographs. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Itraconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); AmLODIPine; Benzhydrocodone; Buprenorphine; Gefitinib; HYDROcodone; Praziquantel; Telithromycin; Vinorelbine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dabrafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daclatasvir.  Management: Decrease the daclatasvir dose to 30 mg once daily if combined with a strong CYP3A4 inhibitor.  No dose adjustment is needed when daclatasvir is used with darunavir/cobicistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Darunavir. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib.  Management: This combination should be avoided; consider reducing dasatinib dose if a strong CYP3A4 inhibitor must be used. If using dasatinib 70 mg/day or 100 mg/day, consider reduction to 20 mg/day; if using dasatinib 140 mg/day, consider reduction to 40 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Delamanid.  Management: Increase electrocardiogram (ECG) monitoring frequency if delamanid is combined with strong CYP3A4 inhibitors because the risk for QTc interval prolongation may be increased. Continue frequent ECG assessments throughout the full delamanid treatment period.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dexamethasone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dihydroergotamine: Itraconazole may increase the serum concentration of Dihydroergotamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: Itraconazole may increase the serum concentration of Disopyramide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOCEtaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOCEtaxel.  Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Itraconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat.  Management: Use should be avoided under some circumstances.  See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: Itraconazole may increase the serum concentration of Elvitegravir.  Management: Limit itraconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir-containing products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Itraconazole may increase the serum concentration of Eplerenone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergoloid Mesylates: Itraconazole may increase the serum concentration of Ergoloid Mesylates. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergonovine: Itraconazole may increase the serum concentration of Ergonovine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergotamine: Itraconazole may increase the serum concentration of Ergotamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estazolam: Itraconazole may increase the serum concentration of Estazolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eszopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eszopiclone.  Management: Limit the eszopiclone dose to 2 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased eszopiclone effects and toxicities (eg, somnolence, drowsiness, CNS depression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etizolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Etizolam.  Management: Consider use of lower etizolam doses when using this combination; specific recommendations concerning dose adjustment are not available.  Monitor clinical response to the combination closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs. Etravirine may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole.  Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Evogliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felodipine: Itraconazole may increase the serum concentration of Felodipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fexofenadine: Itraconazole may increase the serum concentration of Fexofenadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).  Management: Use of orally inhaled fluticasone propionate with strong CYP3A4 inhibitors is not recommended.  Use of orally inhaled fluticasone furoate with strong CYP3A4 inhibitors should be done with caution.  Monitor patients using such a combination more closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Itraconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day itraconazole may also require dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May decrease the serum concentration of Itraconazole. Grapefruit Juice may increase the serum concentration of Itraconazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Itraconazole. Management: When this combination is used, the itraconazole should be administered with a non-diet cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ibrutinib.  Management: Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for 7 days or less), interrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imidafenacin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imidafenacin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Itraconazole may increase the serum concentration of Indinavir. Indinavir may increase the serum concentration of Itraconazole.  Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with itraconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of itraconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Strong) may increase isavuconazole serum concentrations.  Management: Combined use is considered contraindicated per US labeling. Lopinavir/ritonavir (and possibly other uses of ritonavir doses less than 400 mg every 12 hours) is treated as a possible exception to this contraindication despite strongly inhibiting CYP3A4.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May decrease the serum concentration of Itraconazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib adult dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lercanidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levobupivacaine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levomilnacipran: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.  Management: Do not exceed a maximum adult levomilnacipran dose of 80 mg/day in patients also receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan. Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of Itraconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macitentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inhibitors. If combined, monitor closely for increased manidipine effects and toxicities. Manidipine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MedroxyPROGESTERone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MedroxyPROGESTERone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meloxicam: Itraconazole may decrease the serum concentration of Meloxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Itraconazole may increase the serum concentration of Methadone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylergonovine: Itraconazole may increase the serum concentration of Methylergonovine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose reduction in patients receiving strong CYP3A4 inhibitors and monitor for increased steroid related adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam: Itraconazole may increase the serum concentration of Midazolam.  Management: Oral midazolam is contraindicated.  Use intravenous midazolam with great caution in patients receiving itraconazole, employing reduced initial doses whenever possible and monitoring closely for enhanced and prolonged effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midostaurin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midostaurin.  Management: Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MiFEPRIStone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 600 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirodenafil.  Management: Consider using a lower dose of mirodenafil when used with strong CYP3A4 inhibitors. Monitor for increased mirodenafil effects/toxicities with the use of this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: May decrease the serum concentration of Itraconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Combined Inhibitors of CYP3A4 and P-glycoprotein may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olaparib.  Management: Avoid use of strong CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxybutynin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Strong) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite oxymorphone may also be increased. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paliperidone: Itraconazole may enhance the QTc-prolonging effect of Paliperidone. Itraconazole may decrease the metabolism of Paliperidone. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.  Management: Reduce the panobinostat dose to 10 mg when it must be used with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Parecoxib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimavanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimavanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may enhance the arrhythmogenic effect of Pimozide. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Pimozide. This increase in serum concentrations may lead to QTc interval prolongation and ventricular arrhythmias.  Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piperaquine: CYP3A4 Inhibitors (Strong) may enhance the QTc-prolonging effect of Piperaquine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Piperaquine.  Management: Avoid the concomitant use of piperaquine and strong CYP3A4 inhibitors when possible. If this combination cannot be avoided, frequent ECG monitoring is recommended due to the increased risk for QTc prolongation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PONATinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.  Management: Per ponatinib U.S. prescribing information, the adult starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pranlukast: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pravastatin: Itraconazole may increase the serum concentration of Pravastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Praziquantel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Itraconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QUEtiapine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.  Management: In quetiapine treated patients, reduce the quetiapine dose to one sixth of the regular dose following strong CYP3A4 inhibitor initiation. In patients receiving strong CYP3A4 inhibitors, initiate quetiapine at the lowest dose and up-titrate as needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Radotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine. Fluconazole and isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Reboxetine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Repaglinide.  Management: The addition of a CYP2C8 inhibitor to this drug combination may substantially increase the magnitude of increase in repaglinide exposure.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retapamulin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.  Management: Avoid this combination in patients less than 2 years old.  No action is required in other populations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ribociclib.  Management: Avoid use of ribociclib with strong CYP3A4 inhibitors when possible; if combined use cannot be avoided, reduce ribociclib dose to 400 mg once daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected. Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic).  Management: Avoid these combinations when possible.  Voriconazole and isavuconazonium are considered contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rilpivirine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Itraconazole may increase the serum concentration of Riociguat.  Management: Consider starting with a reduced riociguat dose of 0.5 mg three times a day.  Patients receiving such a combination should also be monitored extra closely for signs or symptoms of hypotension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Inhibitors of CYP3A4 (Strong) and P-glycoprotein may increase the serum concentration of Rivaroxaban. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: Itraconazole may increase the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rupatadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: This combination should be avoided under some circumstances. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Itraconazole may increase the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving saquinavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: Itraconazole may increase the serum concentration of Sildenafil.  Management: Concurrent itraconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent itraconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: Itraconazole may increase the serum concentration of Sirolimus.  Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Solifenacin. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: The manufacturer recommends not exceeding 5 mg daily of solifenacin during concomitant therapy with ketoconazole, or other potent CYP3A4 enzyme inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUFentanil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: Consider a reduced dose of sunitinib (minimum of 37.5 mg daily) during concomitant use. Concurrent use with itraconazole is not recommended per itraconazole labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Itraconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with itraconazole. Tacrolimus dose reductions will likely be required. The magnitude of this interaction may be greater in older patients.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical). Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tadalafil: Itraconazole may increase the serum concentration of Tadalafil. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tasimelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Telaprevir. Management: Doses of itraconazole greater than 200 mg/day are not recommended in patients receiving telaprevir.  Use extra caution when using these drugs in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: Itraconazole may increase the serum concentration of Telithromycin. Telithromycin may increase the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Itraconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tezacaftor.  Management: When combined with strong CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be administered in the morning, twice a week, approximately 3 to 4 days apart. No evening doses of ivacaftor (150 mg) alone should be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Itraconazole. Management: Limit itraconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended adult dose of tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Triazolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triazolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Udenafil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combo should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Valbenazine.  Management: Reduce the valbenazine dose to 40 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vardenafil: Itraconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil to a max of 5 mg/24 hours  in patients receiving itraconazole 200 mg/day, and a max of 2.5 mg/24 hours in patients receiving itraconazole 400 mg/day. Itraconazole labeling and Staxyn brand of vardenafil both recommend avoiding this combo.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Venetoclax.  Management: These combinations are contraindicated during venetoclax initiation and ramp-up. In patients receiving steady venetoclax doses after completing ramp-up, reduce the venetoclax by at least 75% if strong CYP3A4 inhibitor use cannot be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg daily in patients receiving strong CYP3A4 inhibitors. The original vilazodone dose can be resumed following discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinBLAStine: Itraconazole may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine: Itraconazole may enhance the adverse/toxic effect of VinCRIStine. Itraconazole may increase the serum concentration of VinCRIStine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vindesine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinorelbine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinorelbine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Itraconazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: Itraconazole may increase the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.  Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185416\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Absorption enhanced by food and possibly by gastric acidity. Non-diet cola drinks have been shown to increase the absorption of the capsules in patients with achlorhydria or those taking H<sub>2</sub>-receptor antagonists or other gastric acid suppressors. Grapefruit/grapefruit juice may increase serum levels. Management: Take capsules immediately after meals. Avoid grapefruit juice.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution: Food decreases the bioavailability and increases the time to peak concentration. Management: Take solution on an empty stomach 1 hour before or 2 hours after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185391\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185405\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Dose-related adverse events were observed in animal reproduction studies at maternally toxic doses. Itraconazole exposure during the first trimester of pregnancy has not been associated with congenital malformations; however, an increase in the rate of early fetal loss has been reported (Bar-Oz 2000; DeSantis 2009; Molgaard-Nielsen 2013). Congenital abnormalities (eg, skeletal, genitourinary tract, cardiovascular and ophthalmic malformations, chromosomal abnormalities, and multiple malformations) have been reported during postmarketing surveillance; however, a causal relationship has not been established.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Itraconazole is approved for the treatment of various fungal infections; however, when treatment of a systemic fungal infection is needed in pregnant women, itraconazole should be avoided, especially during the first trimester (Chapman 2008; Galgiani 2005; HHS [OI adult 2017]; Pappas 2016; Perfect 2010; Wheat 2007).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to the potential risk of congenital malformations, the manufacturer recommends that when used for the treatment of onychomycosis in women of reproductive potential, effective contraception should be used during treatment and for 2 months following treatment. Therapy should begin on the second or third day following menses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20682426\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Itraconazole is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother (Sporanox prescribing information 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breastfeeding is recommended in women who are coinfected with HIV to decrease potential transmission of HIV (HHS [perinatal] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185406\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, tablet: Take with food. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution: Take without food, if possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185393\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liver function in patients with preexisting hepatic dysfunction, and in all patients being treated for longer than 1 month; renal function; signs/symptoms of CHF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For invasive aspergillosis (treatment or prolonged prophylaxis), guidelines recommend monitoring serum trough concentrations (IDSA [Patterson 2016]). Consider monitoring serum trough concentrations for other infections; itraconazole has a variable pharmacokinetic profile and high concentrations may increase the risk of adverse events (Lestner 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2523781\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Invasive aspergillosis:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Timing of concentrations:</i> Obtain trough after steady state has been reached (4 to 7 days after therapy initiation); the need for continued or repeat monitoring is a patient specific decision influenced by many factors (eg, infection severity, cost, assay availability) (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Recommended range:</i> Most experts recommend dosing to achieve trough concentrations &gt;0.5 to 1 mcg/mL. Limited data suggest trough concentrations &gt;3 mcg/mL may be associated with increased toxicity (IDSA [Patterson 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185383\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with cytochrome P450 activity, decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting cell membrane formation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185400\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Requires gastric acidity; capsule or tablet better absorbed with food, solution better absorbed on empty stomach</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub> (average): &gt;700 L; highly lipophilic and tissue concentrations are higher than plasma concentrations. The highest concentrations: adipose, omentum, endometrium, cervical and vaginal mucus, and skin/nails. Aqueous fluids (eg, CSF and urine) contain negligible amounts; distributes into bronchial exudate and sputum</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: 99.8%; metabolite hydroxy-itraconazole: 99.6%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via CYP3A4 into &gt;30 metabolites including hydroxy-itraconazole (major metabolite); appears to have in vitro antifungal activity. Main metabolic pathway is oxidation; may undergo saturation metabolism with multiple dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Variable, ~55% increases by 30% under fasted conditions (oral solution); <b>Note:</b> Oral solution has a higher degree of bioavailability (149% &plusmn; 68%) relative to oral capsules; should not be interchanged</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children (6 months to 12 years): Oral solution: ~36 hours; Metabolite hydroxy-itraconazole: ~18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral: Single dose: 16 to 28 hours, Multiple doses: 42 to 49 hours; Cirrhosis (single dose): 37 hours (range: 20 to 54 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Capsules/tablets: 2 to 5 hours; Oral solution: 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;0.03% active drug, 35% as inactive metabolites); feces (54%; ~3% to 18% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185404\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Itraconazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $278.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Sporanox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $952.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Sporanox Pulsepak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (28): $891.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sporanox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (150 mL): $386.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Onmel Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (14): $633.98</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185407\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Canadiol (ES);</li>\n      <li>Candistat (IN);</li>\n      <li>Canditral (ET, PE, PH, SG, TH, VN, ZW);</li>\n      <li>Chme (TW);</li>\n      <li>Cladosol (LV);</li>\n      <li>Conazole (JO);</li>\n      <li>Funginox (LB);</li>\n      <li>Fungitrazol (ID);</li>\n      <li>Fungizol (EC);</li>\n      <li>Hantrazol (KR);</li>\n      <li>Hitrazole (KR);</li>\n      <li>Icomein (TW);</li>\n      <li>Icon (LK);</li>\n      <li>Iconal (BD);</li>\n      <li>Ikonaz (HR);</li>\n      <li>Inox (ET, HK, LK, MY, PH, TZ);</li>\n      <li>Isox (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Itcozol (NZ);</li>\n      <li>Itol (BD);</li>\n      <li>Itra (BD, KR, TH);</li>\n      <li>Itrac (HR);</li>\n      <li>Itracon (BD, HK, KR, SG, TH);</li>\n      <li>Itrafung (EC);</li>\n      <li>Itragen (CO);</li>\n      <li>Itramed (LK);</li>\n      <li>Itranax (MX);</li>\n      <li>Itranol (IL);</li>\n      <li>Itranols (LV);</li>\n      <li>Itrasix (TH);</li>\n      <li>Itraspor (TR);</li>\n      <li>Itrazol (JO, MY, QA);</li>\n      <li>Itrazole (NZ);</li>\n      <li>Itrizole (JP);</li>\n      <li>Itrol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Itzol (ID);</li>\n      <li>Konitra (KR);</li>\n      <li>Micogal (RO);</li>\n      <li>Micoral (PE);</li>\n      <li>Mycotrazol (HK);</li>\n      <li>Newtrazole (KR);</li>\n      <li>Norspor (TH);</li>\n      <li>Nufatrac (ID);</li>\n      <li>Omicral (RO);</li>\n      <li>Orugal (LT);</li>\n      <li>Orungal (BG, EE, HR, HU, LV, PL, RU);</li>\n      <li>Orunhal (UA);</li>\n      <li>Orzol (PY);</li>\n      <li>Quali-Itrazole (HK);</li>\n      <li>Sempera (DE);</li>\n      <li>Sinozol (MX);</li>\n      <li>Spazol (TH);</li>\n      <li>Sponex (KR);</li>\n      <li>Sporacid (ID);</li>\n      <li>Sporaksol (UA);</li>\n      <li>Sporal (CY, JO, MT, TH, VN);</li>\n      <li>Sporanox (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CY, CZ, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, ID, IE, IL, IQ, IR, IS, IT, JM, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PR, PT, PY, QA, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Sporanox IV (HK, PH);</li>\n      <li>Sporavast (JO);</li>\n      <li>Spornar (TH);</li>\n      <li>Spyrocon (ID);</li>\n      <li>Trachon (ID);</li>\n      <li>Tracon (QA);</li>\n      <li>Unitrac (SG);</li>\n      <li>Vanoran (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahmad SR, Singer SJ, and Leissa BG, &ldquo;Congestive Heart Failure Associated With Itraconazole,&rdquo; <i>Lancet</i>, 2001, 357(9270):1766-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/11403818/pubmed\" target=\"_blank\" id=\"11403818\">11403818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amichai B and Grunwald MH, &ldquo;Adverse Drug Reactions of the New Oral Antifungal Agents - Terbinafine, Fluconazole, and Itraconazole,&rdquo; <i>Int J Dermatol</i>. 1998, 37(6):410-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/9646122/pubmed\" target=\"_blank\" id=\"9646122\">9646122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andes D, Proctor R, Bush RK, et al. Report of successful prolonged antifungal therapy for refractory allergic fungal sinusitis. <i>Clin Inf Dis</i>. 2000;31(1): 202-204.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bar-Oz B, Moretti ME, Bishai R, et al. Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. <i>Am J Obstet Gynecol</i>. 2000;183(3):617-620.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/10992182/pubmed\" target=\"_blank\" id=\"10992182\">10992182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boelaert J, Schurgers M, Matthys E, et al, &ldquo;Itraconazole Pharmacokinetics in Patients With Renal Dysfunction,&rdquo; <i>Antimicrob Agents Chemother</i>, 1988, 32(10):1595-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/2847635/pubmed\" target=\"_blank\" id=\"2847635\">2847635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 21st ed. American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA, et al, &ldquo;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2008, 46(12):1801-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/18462107/pubmed\" target=\"_blank\" id=\"18462107\">18462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cleary JD, Taylor JW, and Chapman SW, &ldquo;Itraconazole in Antifungal Therapy,&rdquo; <i>Ann Pharmacother</i>, 1992, 26(4):502-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/1315596/pubmed\" target=\"_blank\" id=\"1315596\">1315596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cowie F, Meller ST, Cushing P, et al, &ldquo;Chemoprophylaxis for Pulmonary Aspergillosis During Intensive Chemotherapy,&rdquo; <i>Arch Dis Child</i>, 1994, 70(2):136-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/8129437/pubmed\" target=\"_blank\" id=\"8129437\">8129437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Backer M, De Vroey C, Lesaffre E, et al, &ldquo;Twelve Weeks of Continuous Oral Therapy for Toenail Onychomycosis Caused by Dermatophytes: A Double-Blind Comparative Trial of Terbinafine 250 mg/day Versus Itraconazole 200 mg/day,&rdquo; <i>J Am Acad Dermatol</i>, 1998, 38(5 Pt 3):S57-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/9594939/pubmed\" target=\"_blank\" id=\"9594939\">9594939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. <i>Antimicrob Agents Chemother</i>. 1998;42(2):404-408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/9527794/pubmed\" target=\"_blank\" id=\"9527794\">9527794</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Santis M, Di Gianantonio E, Cesari E, Ambrosini G, Straface G, Clementi M. First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy. <i>Drug Saf</i>. 2009;32(3):239-244.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/19338381/pubmed\" target=\"_blank\" id=\"19338381\">19338381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denning DW, Lee JY, Hostetler JS, et al, &ldquo;NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis,&rdquo; <i>Am J Med</i>, 1994, 97(2):135-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/8059779/pubmed\" target=\"_blank\" id=\"8059779\">8059779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. <i>Clin Infect Dis</i>. 2016;63(6):e112-e146. doi: 10.1093/cid/ciw360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/27470238/pubmed\" target=\"_blank\" id=\"27470238\">27470238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Catanzaro A, Cloud GA, et al; Mycoses Study Group. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. <i>Ann Intern Med</i>. 2000;133(9):676-686.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/11074900/pubmed\" target=\"_blank\" id=\"11074900\">11074900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grant SM and Clissold SP, &ldquo;Itraconazole. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Superficial and Systemic Mycoses,&rdquo; <i>Drugs</i>, 1989, 37(3):310-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/2540949/pubmed\" target=\"_blank\" id=\"2540949\">2540949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haria M, Bryson HM, and Goa KL, &ldquo;Itraconazole: A Reappraisal of Its Pharmacological Properties and Therapeutic Use in the Management of Superficial Fungal Infections,&rdquo; <i>Drugs</i>, 1996, 51(4):585-620.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/8706596/pubmed\" target=\"_blank\" id=\"8706596\">8706596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heymann WR and Manders SM, &ldquo;Itraconazole-Induced Acute Generalized Exanthemic Pustulosis,&rdquo; <i>J Am Acad Dermatol</i>, 1995, 33(1):130-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/7601931/pubmed\" target=\"_blank\" id=\"7601931\">7601931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS, Centers for Disease Control and Prevention (CDC). Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America. Accessed October 23, 2017. Available at <a href=\"http://www.aidsinfo.nih.gov/contentfiles/adult_oi.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/contentfiles/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated April 29, 2016. Accessed May 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS, Centers for Disease Control and Prevention (CDC). Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hope WW, Castagnola E, Groll AH, et al; ESCMID Fungal Infection Study Group. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. <i>Clin Microbil Infect</i>. 2012;18(suppl 7):38-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/23137136/pubmed\" target=\"_blank\" id=\"23137136\">23137136</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jennings TS and Hardin TC, &ldquo;Treatment of Aspergillosis With Itraconazole,&rdquo; <i>Ann Pharmacother</i>, 1993, 27(10):1206-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/8251691/pubmed\" target=\"_blank\" id=\"8251691\">8251691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman CA, Bustamante B, Chapman SW, et al, &quot;Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(10):1255-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/17968818/pubmed\" target=\"_blank\" id=\"17968818\">17968818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE, Rollins CJ, Yee WJ, et al, &ldquo;Low Itraconazole Serum Concentrations Following Administration of Itraconazole Suspension to Critically Ill Allogenic Bone Marrow Transplant Recipients,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(2):140-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/7756712/pubmed\" target=\"_blank\" id=\"7756712\">7756712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohr J, Johnson M, Cooper T, et al, &ldquo;Current Options in Antifungal Pharmacotherapy,&rdquo; <i>Pharmacotherapy</i>, 2008, 28(5):614-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/18447660/pubmed\" target=\"_blank\" id=\"18447660\">18447660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&oslash;lgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. <i>N Engl J Med</i>. 2013;369(9):830-839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/23984730/pubmed\" target=\"_blank\" id=\"23984730\">23984730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neuvonen PJ, Backman JT, and Niemi M, &ldquo;Pharmacokinetic Comparison of the Potential Over-The-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin,&rdquo; <i>Clin Pharmacokinet,</i> 2008, 47(7):463-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/18563955/pubmed\" target=\"_blank\" id=\"18563955\">18563955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Onmel (itraconazole) [prescribing information]. Greensboro, NC: Merz Pharmaceuticals; November 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html. Accessed August 8, 2016.27365388</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sedlak T, Shufelt C, Iribarren C, et al, &quot;Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval,&quot; <i>Ann Noninvasive Electrocardiol</i>, 2013, 18(4):389-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/23879279/pubmed\" target=\"_blank\" id=\"23879279\">23879279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sporanox (itraconazole) capsules [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sporanox (itraconazole capsules) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sporanox (itraconazole) oral solution [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sporanox Oral Solution (itraconazole) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrell CL, &ldquo;Antifungal Agents. Part II. The Azoles,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(1):78-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/9987539/pubmed\" target=\"_blank\" id=\"9987539\">9987539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobon AM, Franco L, Espinal D, et al, &ldquo;Disseminated Histoplasmosis in Children: The Role of Itraconazole Therapy,&rdquo; <i>Pediatr Infect Dis J</i>, 1996; 15:1002-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trepanier EF and Amsden GW, &ldquo;Current Issues in Onchomycosis,&rdquo; <i>Ann Pharmacother</i>, 1998, 32(2):204-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/9496407/pubmed\" target=\"_blank\" id=\"9496407\">9496407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tucker RM, Haq Y, Denning DW, et al, &ldquo;Adverse Effects Associated With Itraconazole in 189 Patients on Chronic Therapy,&rdquo; <i>J Antimicrob Chemother</i>, 1990, 26(4):561-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/2174854/pubmed\" target=\"_blank\" id=\"2174854\">2174854</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheat J, Freifeld AG, Kleiman MB, et al, &ldquo;Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2007, 45(7):807&ndash;25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/17806045/pubmed\" target=\"_blank\" id=\"17806045\">17806045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheat J, Hafner R, Korzun AH, et al, &ldquo;Itraconazole Treatment of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome,&rdquo; <i>Am J Med</i>, 1995, 98(4):336-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/7709945/pubmed\" target=\"_blank\" id=\"7709945\">7709945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/itraconazole-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8586 Version 234.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708958\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F185420\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F185421\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F185468\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F185425\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F185447\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F185426\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F185427\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F185428\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F185395\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F185380\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F185398\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F185396\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45504494\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F185476\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F185387\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F185401\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F185384\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F185462\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F185389\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F185416\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F185391\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F185405\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20682426\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F185406\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F185393\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F2523781\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F185383\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F185400\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F185404\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F185407\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8586|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=itraconazole-patient-drug-information\" class=\"drug drug_patient\">Itraconazole: Patient drug information</a></li><li><a href=\"topic.htm?path=itraconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Itraconazole: Pediatric drug information</a></li></ul></div></div>","javascript":null}